Recently, it has been shown that drimane-type sesquiterpenoids isolated from Zygogynum pancheri, a species native to New Caledonia, possessed significant α-amylase inhibitory activities. To further explore their antidiabetic potential, we investigated the effect of 1β-O-(E-cinnamoyl)-6α-hydroxy-9epi-polygodial (D) and 1β-E-O-p-methoxycinnamoyl-bemadienolide (L), two of the most active compounds of the series, on diabetic model rats. Compounds D and L (2 mg kg/day) were daily and orally administrated for 30 days to streptozotocin (STZ) (150 mg/kg) induced male diabetic Wistar rats. Animals were allocated into five groups of six rats. Comparatively to diabetic rats, treatments with D and L compounds were able to significantly (P < 0.05) decrease Fasting Blood Glucose (FBG) (70.15%, 71.02%), serum total cholesterol (46.27% and 39.38%), triglycerides (56.60% and 58.15%), creatinine (37.31% and 36.49%) and uric acid levels (67.76% and 69.68%), respectively. Compounds D and L also restored the altered plasma enzyme (aspartate aminotransferase, AST (47.83% and 43.20%), alanine aminotransferase, ALT (49.76% and 48.35%, alkaline phosphatase, ALP (72.78% and 73.21%)) and lactate dehydrogenase, LDH (47.95% and 53.93%) levels to near normal, respectively. Administration of Glymepiride, significantly (p < 0.05) reduced FBG (73.94%) in STZ induced diabetic rats. Additionally, the compounds D and L exhibited inhibitory effects in vivo on lipase activity of diabetic rats (54.83% and 52.25%), respectively. The outcomes of this study suggested that these two drimanes could be considered as efficient hypoglycemic, hypolipidemic and antiobesity agents for diabetes management and its complications.

最近，已经显示从新喀里多尼亚原生种的合子（Zygogynum pancheri）分离的drimane型倍半萜类具有显着的α-淀粉酶抑制活性。为了进一步探讨其抗糖尿病的潜力，我们研究了1β- O-（E-肉桂酰基）-6α-羟基-9 Epi - polygodial（D）和1β- E - O - p的作用-甲氧基肉桂酰基-甜菜烯内酯（L），该系列中最活跃的两种化合物，用于糖尿病模型大鼠。每天将化合物D和L（2mg kg /天）口服给予链脲佐菌素（STZ）（150mg / kg）诱导的雄性糖尿病Wistar大鼠，持续30天。将动物分为五组，每组六只大鼠。与糖尿病大鼠相比，用D和L化合物治疗可显着（P <0.05）降低空腹血糖（FBG）（70.15％，71.02％），血清总胆固醇（46.27％和39.38％），甘油三酸酯（56.60％和58.15％），肌酐（37.31％和36.49％）和尿酸水平（分别为67.76％和69.68％）。化合物D和L还恢复了改变的血浆酶（天冬氨酸转氨酶，AST（47.83％和43.20％），丙氨酸转氨酶，ALT（49.76％和48.35％），碱性磷酸酶，ALP（72.78％和73.21％）和乳酸脱氢酶， LDH（分别为47.95％和53.93％）达到接近正常水平。格列美脲的施用显着（p  <0.05）降低了STZ诱导的糖尿病大鼠的FBG（73.94％）。此外，化合物D和L在体内具有抑制作用对糖尿病大鼠脂肪酶活性的影响分别为54.83％和52.25％。这项研究的结果表明，这两种drimane可以被认为是糖尿病管理及其并发症的有效降糖，降血脂和抗肥胖药。